Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV- hGAA ) Gene Therapy in Children Affected by Pompe Disease
Restricted accessResearch articleFirst published online December, 2017
Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV- hGAA ) Gene Therapy in Children Affected by Pompe Disease
A first-in-human trial of diaphragmatic gene therapy (AAV1-CMV-GAA) to treat respiratory and neural dysfunction in early-onset Pompe disease was conducted. The primary objective of this study was to assess the safety of rAAV1-CMV-hGAA vector delivered to the diaphragm muscle of Pompe disease subjects with ventilatory insufficiency. Safety was assessed by measurement of change in serum chemistries and hematology, urinalysis, and immune response to GAA and AAV, as well as change in level of health. The data demonstrate that the AAV treatment was safe and there were no adverse events related to the study agent. Adverse events related to the study procedure were observed in subjects with lower baseline neuromuscular function. All adverse events were resolved before the end of the study, except for one severe adverse event determined not to be related to either the study agent or the study procedure. In addition, an anti-capsid and anti-transgene antibody response was observed in all subjects who received rAAV1-CMV-hGAA, except for subjects who received concomitant immunomodulation to manage reaction to enzyme replacement therapy, as per their standard of care. This observation is significant for future gene therapy studies and serves to establish a clinically relevant approach to blocking immune responses to both the AAV capsid protein and transgene product.
HirschhornR, ReuserAJ. Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency. In: ScriverCR, BeaudetAL, SlyW, et al., eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw Hill, 2001:3389–3420.
3.
MartinJJ, de BarsyT, van HoofF, et al.Pompe's disease: an inborn lysosomal disorder with storage of glycogen. A study of brain and striated muscle. Acta Neuropathol, 1973; 23:229–244.
4.
RabenN, PlotzP, ByrneBJ. Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med, 2002; 2:145–166.
5.
KroosM, Hoogeveen-WesterveldM, van der PloegA, et al.The genotype–phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet, 2012; 160C:59–68.
6.
ACMG Work Group on Management of Pompe Disease; KishnaniPS, SteinerRD, et al.Pompe disease diagnosis and management guideline. Genet Med, 2006; 8:267–288.
7.
SlonimAE, BuloneL, RitzS, et al.Identification of two subtypes of infantile acid maltase deficiency. J Pediatr, 2000; 137:283–285.
8.
ElmallahMK, FalkDJ, NayakS, et al.Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. Mol Ther, 2014; 22:702–712.
9.
ChanJ, DesaiAK, KaziZB, et al.The emerging phenotype of late-onset Pompe disease: a systematic literature review. Mol Genet Metab, 2017; 120:163–172.
10.
FernandezC, LegidoA, JethvaR, et al.Correction of a short cardiac PR interval in a 12-year-old girl with late-onset Pompe disease following enzyme replacement therapy. Genet Med, 2012; 14:757–758.
11.
van CapelleCI, van der BeekNA, HagemansML, et al.Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study. Neuromuscul Disord, 2010; 20:775–782.
12.
JureckaA, ZuberuberZ, Opoka-WiniarskaV, et al.Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature. Mol Genet Metab, 2012; 107:508–512.
13.
ToscanoA, SchoserB. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol, 2013; 260:951–959.
14.
ChenCA, ChienYH, HwuWL, et al.Left ventricular geometry, global function, and dyssynchrony in infants and children with pompe cardiomyopathy undergoing enzyme replacement therapy. J Card Fail, 2011; 17:930–936.
15.
ByrneBJ, KishnaniPS, CaseLE, et al.Pompe disease: design, methodology, and early findings from the Pompe Registry. Mol Genet Metab, 2011; 103:1–11.
16.
OhashiT, IizukaS, ShimadaY, et al.Administration of anti-CD3 antibodies modulates the immune response to an infusion of alpha-glucosidase in mice. Mol Ther, 2012; 20:1924–1931.
17.
de VriesJM, van der BeekNA, KroosMA, et al.High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab, 2010; 101:338–345.
18.
KishnaniPS, DicksonPI, MuldowneyL, et al.Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Mol Genet Metab, 2016; 117:66–83.
19.
NayakS, SivakumarR, CaoO, et al.Mapping the T helper cell response to acid alpha-glucosidase in Pompe mice. Mol Genet Metab, 2012; 106:189–195.
PatelTT, BanugariaSG, CaseLE, et al.The impact of antibodies in late-onset Pompe disease: a case series and literature review. Mol Genet Metab, 2012; 106:301–309.
22.
KikuchiT, YangHW, PennybackerM, et al.Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail. J Clin Invest, 1998; 101:827–833.
23.
RabenN, DanonM, GilbertAL, et al.Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab, 2003; 80:159–169.
24.
DeRuisseauLR, FullerDD, QiuK, et al.Neural deficits contribute to respiratory insufficiency in Pompe disease. Proc Natl Acad Sci U S A, 2009; 106:9419–9424.
25.
FullerDD, ElMallahMK, SmithBK, et al.The respiratory neuromuscular system in Pompe disease. Respir Physiol Neurobiol, 2013; 189:241–249.
26.
ToddAG, McElroyJA, GrangeRW, et al.Correcting neuromuscular deficits with gene therapy in Pompe disease. Ann Neurol, 2015; 78:222–234.
27.
MahCS, FalkDJ, GermainSA, et al.Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Mol Ther, 2010; 18:502–510.
28.
SmithBK, CollinsSW, ConlonTJ, et al.Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum Gene Ther, 2013; 24:630–640.
29.
ByrnePI, CollinsS, MahCC, et al.Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV-GAA) gene vector in patients with Pompe disease. Hum Gene Ther Clin Dev, 2014; 25:134–163.
30.
SmithBK, MartinAD, LawsonLA, et al.Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: clinical evidence of respiratory plasticity. Exp Neurol, 2017; 287:216–224.
31.
MahC, FraitesTJJr, CresawnKO, et al.A new method for recombinant adeno-associated virus vector delivery to murine diaphragm. Mol Ther, 2004; 9:458–463.
32.
ConlonTJ, ErgerK, PorvasnikS, et al.Preclinical toxicology and biodistribution studies of recombinant adeno-associated virus 1 human acid alpha-glucosidase. Hum Gene Ther Clin Dev, 2013; 24:127–133.
33.
ElderME, NayakS, CollinsSW, et al.B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr, 2013; 163:847–854.e1.
34.
CortiM, ElderM, FalkD, et al.B-Cell depletion is protective against anti-AAV capsid immune response: a human subject case study. Mol Ther Methods Clin Dev, 2014; 1.
35.
Hobson-WebbLD, ProiaAD, ThurbergBL, et al.Autopsy findings in late-onset Pompe disease: a case report and systematic review of the literature. Mol Genet Metab, 2012; 106:462–469.
36.
KretzschmarHA, WagnerH, HubnerG, et al.Aneurysms and vacuolar degeneration of cerebral arteries in late-onset acid maltase deficiency. J Neurol Sci, 1990; 98:169–183.
37.
AnneserJM, PongratzDE, PodskarbiT, et al.Mutations in the acid alpha-glucosidase gene (M. Pompe) in a patient with an unusual phenotype. Neurology, 2005; 64:368–370.
38.
McIntoshPT, Hobson-WebbLD, KaziZB, et al.Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy. Mol Genet Metab, 2017Oct13 [Epub ahead of print]; DOI: 10.1016/j.ymgme.2017.10.005.
39.
BraunsdorfWE. Fusiform aneurysm of basilar artery and ectatic internal carotid arteries associated with glycogenosis type 2 (Pompe's disease). Neurosurgery, 1987; 21:748–749.
40.
BrettschneiderJ, SperfeldAD, LudolphAC, et al.Intracerebral hemorrhage in a patient with glycogenosis type II (Pompe disease): is there a pathophysiological relationship?. Muscle Nerve, 2008; 38:1211–1212.
41.
GaribaldiM, SacconiS, AntoniniG, et al.Long term follow-up of cerebrovascular abnormalities in late onset Pompe disease (LOPD). J Neurol, 2017; 264:589–590.
42.
HenselO, HanischF, StockK, et al.Morphology and function of cerebral arteries in adults with pompe disease. JIMD Rep, 2015; 20:27–33.
43.
LaforetP, PetiotP, NicolinoM, et al.Dilative arteriopathy and basilar artery dolichoectasia complicating late-onset Pompe disease. Neurology, 2008; 70:2063–2066.
44.
MakosMM, McCombRD, HartMN, et al.Alpha-glucosidase deficiency and basilar artery aneurysm: report of a sibship. Ann Neurol, 1987; 22:629–633.
45.
MatsuokaY, SendaY, HirayamaM, et al.Late-onset acid maltase deficiency associated with intracranial aneurysm. J Neurol, 1988; 235:371–373.
46.
MiyamotoY, EtohY, JohR, et al.Adult-onset acid maltase deficiency in siblings. Acta Pathol Jpn, 1985; 35:1533–1542.
47.
PericS, FumicK, BilicK, et al.Rupture of the middle cerebral artery aneurysm as a presenting symptom of late-onset Pompe disease in an adult with a novel GAA gene mutation. Acta Neurol Belg, 2014; 114:165–166.
48.
QuenardelleV, BataillardM, BazinD, et al.Pompe disease presenting as an isolated generalized dilative arteriopathy with repeated brain and kidney infarcts. J Neurol, 2015; 262:473–475.
49.
RefaiD, LevR, CrossDT, et al.Thrombotic complications of a basilar artery aneurysm in a young adult with Pompe disease. Surg Neurol, 2008; 70:518–520.
SacconiS, BocquetJD, ChanaletS, et al.Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe disease. J Neurol, 2010; 257:1730–1733.
52.
SandhuD, RizviA, KimJ, et al.Diffuse cerebral microhemorrhages in a patient with adult-onset Pompe's disease: a case report. J Vasc Interv Neurol, 2014; 7:82–85.
53.
ZhangB, ZhaoY, LiuJ, et al.Late-onset Pompe disease with complicated intracranial aneurysm: a Chinese case report. Neuropsychiatr Dis Treat, 2016; 12:713–717.
54.
PichiecchioA, SaccoS, De FilippiP, et al.Late-onset Pompe disease: a genetic-radiological correlation on cerebral vascular anomalies. J Neurol, 2017Oct; 264:2110–2118.
55.
MontagneseF, BarcaE, MusumeciO, et al.Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment. J Neurol, 2015; 262:968–978.
56.
WensSC, KuperusE, Mattace-RasoFU, KruijshaarME, BrusseE, van MontfortKC, de BoerMS, SijbrandsEJ, van der PloegAT, van DoornPA. Increased aortic stiffness and blood pressure in non-classic Pompe disease. J Inherit Metab Dis, 2014; 37:391–397.
57.
SchullerA, WenningerS, Strigl-PillN, et al.Toward deconstructing the phenotype of late-onset Pompe disease. Am J Med Genet C Semin Med Genet, 2012; 160C:80–88.
58.
CalcedoR, WilsonJM. Humoral immune response to AAV. Front Immunol, 2013; 4:341.
59.
MasatE, PavaniG, MingozziF. Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions. Discov Med, 2013; 15:379–389.
60.
MingozziF, HighKA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood, 2013; 122:23–36.
61.
FerreiraV, TwiskJ, KwikkersK, et al.Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a Phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum Gene Ther, 2014; 25:180–188.
62.
ScallanCD, JiangH, LiuT, et al.Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood, 2006; 107:1810–1817.
63.
MurphySL, LiH, ZhouS, et al.Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver. Mol Ther, 2008; 16:138–145.
64.
JiangH, CoutoLB, Patarroyo-WhiteS, et al.Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood, 2006; 108:3321–3328.
65.
MannoCS, PierceGF, ArrudaVR, et al.Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med, 2006; 12:342–347.
66.
CortiM, CleaverB, ClementN, et al.Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in Pompe disease: preclinical to clinical planning. Hum Gene Ther Clin Dev, 2015; 26:185–193.
67.
KozarskyKF, McKinleyDR, AustinLL, et al.In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem, 1994; 269:13695–13702.
68.
GaoGP, LuF, SanmiguelJC, et al.Rep/Cap gene amplification and high-yield production of AAV in an A549 cell line expressing Rep/Cap. Mol Ther, 2002; 5:644–649.
69.
UnzuC, Hervas-StubbsS, SampedroA, et al.Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. J Transl Med, 2012; 10:122.
70.
SackBK, MerchantS, MarkusicDM, et al.Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy. PLoS One, 2012; 7:e37671.
71.
MingozziF, ChenY, MurphySL, et al.Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B. Mol Ther, 2012; 20:1410–1416.
72.
FontanellasA, Hervas-StubbsS, MauleonI, et al.Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates. Mol Ther, 2010; 18:754–765.
73.
LimonJJ, FrumanDA. Akt and mTOR in B cell activation and differentiation. Front Immunol, 2012; 3:228.
74.
NayakS, CaoO, HoffmanBE, et al.Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells. J Thromb Haemost, 2009; 7:1523–1532.
75.
MoghimiB, SackBK, NayakS, et al.Induction of tolerance to factor VIII by transient co-administration with rapamycin. J Thromb Haemost, 2011; 9:1524–1533.
76.
BestardO, CassisL, CruzadoJM, et al.Costimulatory blockade with mTor inhibition abrogates effector T-cell responses allowing regulatory T-cell survival in renal transplantation. Transpl Int, 2011; 24:451–460.
NayakS, SarkarD, PerrinGQ, et al.Prevention and reversal of antibody responses against Factor IX in gene therapy for hemophilia B. Front Microbiol, 2011; 2:244.
79.
LiuCL, YeP, LinJ, et al.Anti-CD20 as the B-cell targeting agent in a combined therapy to modulate anti-Factor VIII immune responses in hemophilia A inhibitor mice. Front Immunol, 2014; 4:502.
80.
MendellJR, Al-ZaidyS, ShellR, et al.Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med, 2017; 377:1713–1722.
